Mesa Labs posts investor presentation on life science tools for regulated-market quality control

Mesa Laboratories

MLAB

0.00

Mesa Laboratories investor presentation highlighted FY26 revenue of USD 249.13 million, up 3.4% year over year.
Gross margin 63.5%; adjusted operating income excluding unusual items USD 63.49 million, or 25.5% of revenue.
Segment revenue mix: Sterilization and Disinfection Control USD 101.6 million; Calibration Solutions USD 53.6 million; Biopharmaceutical Development USD 48.6 million.
Clinical Genomics revenue USD 45.4 million; management flagged ongoing China contraction, now under 10% of segment revenue.
Balance-sheet focus outlined with cash of USD 26.9 million; total net leverage ratio 2.11 under the credit facility definition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesa Laboratories Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.